Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cefotiam is a second-generation cephalosporin antibiotic with broad-spectrum activity against both Gram-positive and Gram-negative bacteria. It acts by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. Cefotiam is primarily used for the treatment of various bacterial infections, including those caused by Staphylococcus, Streptococcus, Pneumococcus, Haemophilus influenzae, Escherichia coli, Klebsiella species, Enterobacteriaceae family members and others. Clinical indications include osteomyelitis, septic arthritis, tonsillitis, bronchitis (acute and chronic), pneumonia, gynecological infections, sepsis as well as otitis media and sinusitis[1][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cefotiam.